|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Dysregulated m:croRNAs in the pathogenesis and progression of cervical neoplasm显示文摘 | Cheung T Man KM Yu M | 2012 | Cell Cycle2012，11，15： | 1 |
| 3 | The doctor - patient relationship and malpractice 显示文摘 | Beckman HB Markakis KM Such- man AL | 1994 | Arch Intern Med1994，154，12： | 1 |
| 4 | Co-regulation and interdependence of mammalian epidermal permeability and antimicrobial barriers显示文摘 | Aberg KM Man MQ Gallo RL | 2008 | J Invest Dermatol2008，128，4： | 1 |
| 5 | Co-regulation and interde- pendence of the mammalian epidermal permeability and antimicro-bial barriers显示文摘 | Aberg KM Man MQ Gallo RL | 2008 | J Invest Dermatol2008，128，4： | 1 |
| 6 | Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders显示文摘 | Shen JL Man KM Huang PH | 2010 | Molecules2010，15，9： | 1 |
| 7 | Evaluation of PEG-transferrin- PEI nanocomplex as a gene delivery agent 显示文摘 | Man Lee KM Lee YB Oh IJ | 2011 | J Nanosci Nanotechnol2011，11，70： | 1 |
| 8 | Evaluation of the performance of a modified Acute Physiology and Chronic Health Evaluation (APACHE Ⅱ)scoring system for critically ill patients in emergency departments in Hong Kong显示文摘 | Man SY Chan KM Wong FY | | 0，，： | 1 |
| 9 | Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample显示文摘 | Cornish KM Manly T Savage R | 2005 | Mol Psychiatry2005，10，7： | 1 |
| 10 | Composite auditory evoked potential index versus bispectral index to estimate the level of sedation in paralyzed critically ill patients: a prospective observational study显示文摘 | Lu CH Man KM Ou-Yang HY | 2008 | Anesth Analg2008，107，4： | 1 |
| 11 | Association of interleukin-18 genepolymorphisms with calcium oxalate kidney stone disease显示文摘 | Lai KC Lin WY Man KM | 2010 | Scand J Urol Nephrol2010，44，1： | 1 |
| 12 | Prospective study of aspirin use and risk of stroke in women 显示文摘 | Iso H Hennekens CH Stampfer MJ R exrode KM Colditz GA Speizer FE Willett WC Man Son JE | 1999 | Stroke1999，30，9： | 1 |
| 13 | Transcntaneous electrical nerve stimulation on ST36 and SP6 acupoints prevents hyperglycaemic response during anaesthesia: a randomised controlled tfia显示文摘 | Man KM Man SS Shen JL | 2011 | Eur J Anaesthesiol2011，28，6： | 1 |
| 14 | Identification of HLA-DR1-and HLA- DR15-restricted human papillomavirus type 16 (HPV16) and HPV 18 E6 epitopes recognized by CD4+ T cells from healthy young women显示文摘 | Gallagher KM Man S | 2007 | J Gen Virol2007，88，5： | 1 |
| 15 | Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers显示文摘 | Aberg KM Man MQ Gallo RL | 2008 | J Invest Dermatol2008，128，4： | 1 |
| 16 | Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders显示文摘 | Shen JL Man KM Huang PH | 2010 | Moleeules2010，15，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员